Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 398 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: hemoglobin A1c Clear all

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 11
States / cities: Concord, California • Sacramento, California • Denver, Colorado + 8 more

Conditions: Diabetes Mellitus, Type 2, PreDiabetes, Pancreas Cyst, Chronic Pancreatitis, Genetic Predisposition to Disease, Inherited Disease
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Diabetes Mellitus, Type 2
Interventions: Canakinumab, Metformin, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 18
States / cities: Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more

Conditions: Diabetes Mellitus Type 2
Interventions: DPP-IV Inhibitor, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 18
States / cities: Salinas, California • Clearwater, Florida • Hialeah, Florida + 15 more

Conditions: Type1diabetes
Interventions: 4T Education and Care; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 21 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diabetes Mellitus, Type 2
Interventions: exenatide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2006
U.S. locations: 60
States / cities: Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more

Conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions: Enrollment in existing SDRI diabetes education programs; Behavioral
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Pioglitazone 45 mg, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pre-diabetes, Type II Diabetes, Insulin Resistance
Interventions: Not listed
Lead sponsor: PeriRx; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets; Diagnostic Test · Behavioral
Lead sponsor: MacroGenics; Industry
Eligibility: 10 Years to 37 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetes Mellitus, Healthy
Interventions: Breath carbon monoxide measurement; Diagnostic Test
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: LoBag Diet - test phase, LoBAG Diet - control phase; Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 55 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabete Type 2
Interventions: Intensification of insulin regimen/Nutrition; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes Mellitus, Type 2
Interventions: rosiglitazone/metformin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 49
States / cities: Anniston, Alabama • Chandler, Arizona • Phoenix, Arizona + 41 more

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK523338; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 43
States / cities: Tucson, Arizona • Fresno, California • Wheat Ridge, Colorado + 38 more

Conditions: Type 2 Diabetes
Interventions: Lysulin; Dietary Supplement
Lead sponsor: Juraj Koska; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Diabetes, Nutrition
Interventions: CGM Device; Device
Lead sponsor: Sutter Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Type 2 Diabetes
Interventions: HM11260C, liraglutide, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: CA, California

Conditions: Axial Spondyloarthritis
Interventions: Dietary recommendations; Other
Lead sponsor: Viome; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Chronic Periodontitis, Type 2 Diabetes
Interventions: Non-surgical periodontal therapy, Delayed non-surgical periodontal therapy; Procedure · Other
Lead sponsor: Stony Brook University; Other
Eligibility: 35 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Birmingham, Alabama • Minneapolis, Minnesota • Stony Brook, New York + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 1356, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • National City, California + 9 more

Conditions: Diabetes
Interventions: Not listed
Lead sponsor: Quotient Diagnostics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Escondido, California • Chaska, Minnesota • Columbia, Missouri

Conditions: Gestational Diabetes Mellitus in Pregnancy, Pregnancy, High Risk
Interventions: Enhanced First Trimester GDM Screening, Routine Gestational Diabetes Screening; Diagnostic Test
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Type 1 Diabetes (T1D)
Interventions: T1D-specific depression SSI, T1D Educational; Behavioral
Lead sponsor: Nemours Children's Health System; Other
Eligibility: 12 Years to 17 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

Blood Markers of Early Pancreas Cancer

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

Integrating Abbott Point-of-Care Technologies and the Community Scientist Model to Support HbA1c Testing Per ADA

Dapagliflozin Plus Pioglitazone in T1DM

Salivary Transcriptome Biomarkers for Early Diabetes Detection

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

Exhaled Carbon Monoxide and Red Blood Cell Turnover

Effect of a High Protein Diet on the 24-hour Profile of Ghrelin, GH (Growth Hormone) and IGF-1 (Insulin-like Growth Factor-1)

Reversibility of Brain Glucose Transport and Metabolism in T2DM: an Intervention Study

A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics

A Study In Patients With Type 2 Diabetes Mellitus

The Effect of Lysulin on Glycemic Control and Advanced Glycation

Salud Diabetes: A Pilot Study Comparing Lifestyle Interventions and Real-Time Continuous Glucose Monitoring

Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Microbiome and Axial Spondyloarthritis

Diabetes and Periodontal Therapy Trial

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System

Early Detection of Gestational Diabetes Mellitus in Pregnancy

Adapting Single Sessions Interventions for Type 1 Diabetes